Whole body MRI is effective for identifying metastatic disease in colorectal cancer patients

BMJ ◽  
2019 ◽  
pp. l5453
Author(s):  
Rob Cook ◽  
Peter Davidson ◽  
Rosie Martin
Keyword(s):  
Colorectal Cancer ◽  
Diagnostic Accuracy ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Health Technology ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Whole Body Mri ◽  
Health Technology Assessment Programme ◽  
Colorectal Cancer Patients

The studyTaylor S, Mallett S, Beare S et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. Lancet Gastroenterol Hepatol 2019;4:529-37.This project was funded by the NIHR Health Technology Assessment Programme (project number 10/68/01).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000797/identifying-metastatic-disease-in-colorectal-cancer-with-whole-body-mri

scholarly journals Unmet Need for Symptom Management in a Newly Diagnosed Population of Lung and Colorectal Cancer Patients (412-C)

2012 ◽  
Vol 43 (2) ◽  
pp. 377-378
Author(s):  
Anne Walling ◽  
Jane Weeks ◽  
Katherine Kahn ◽  
Diana Tisnado ◽  
Nancy Keating ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Symptom Management ◽  
Unmet Need ◽  
Newly Diagnosed ◽  
Colorectal Cancer Patients

Association between pretreatment Fusobacterium nucleatum and cancer pain at six months postsurgery in newly diagnosed colorectal cancer patients: Results from the ColoCare Study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3581-3581
Author(s):  
Anita Roselyn Peoples ◽  
Biljana Gigic ◽  
Jennifer Ose ◽  
Andreana Natalie Holowatyj ◽  
Patrick M. Mallea ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Pain ◽  
Cancer Patients ◽  
Fusobacterium Nucleatum ◽  
Tumor Stage ◽  
Life Questionnaire ◽  
Newly Diagnosed ◽  
European Organization ◽  
Post Surgery ◽  
Colorectal Cancer Patients

3581 Background: Pain is a prevalent, debilitating symptom in more than half of cancer patients. Accumulating evidence suggests a bi-directional relationship between gut microbiota and pain, potentially via inflammation and oxidative stress. Fusobacterium nucleatum (Fn), a pro-inflammatory anaerobic bacterium, is frequently detected in colorectal cancer (CRC) patients. To date, no study has identified a relationship between Fn and cancer pain in CRC patients. We investigated the associations between pre-treatment Fn and cancer pain at 6 months post-surgery in CRC patients. Methods: We utilized pre-surgery stool samples collected from 80 prospectively followed, newly diagnosed CRC patients recruited from the German site of the international ColoCare Study. Eligible patients were neo-adjuvant treatment naïve and did not use antibiotics for at least 1 month before stool collection. Fn DNA was assessed via quantitative real-time polymerase chain reaction. Patients were median split into Fn-high (>17.27; n=40) or Fn-low (≤17.27; n=40). Cancer pain was assessed using the 2 pain symptom items from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core-30 (lower score=lower pain) at pre- and 6 months post-surgery. Results: Before surgery, 48% of all patients reported any pain. At 6 months post-surgery, we observed a decrease in cancer pain by 33% for Fn-low, while there was an increase in cancer pain by 41% for Fn-high. After controlling for pre-surgery cancer pain in ANCOVA model, we observed significantly higher mean cancer pain at 6 months post-surgery in the Fn-high group vs. the Fn-low group (24.07 vs. 13.44; effect size, ES=0.45; p=0.04). These results were maintained even after controlling for age, sex, tumor stage and site, adjuvant chemotherapy, BMI, physical activity, and any pain medications (29.11 vs. 16.55; ES=0.53; p=0.03). Conclusions: These findings suggest that high Fn is an independent predictor of cancer pain at 6 months post-surgery in colorectal cancer patients. Further research is needed to confirm and understand the mechanisms of these results. Funding: NCI U01 CA206110.

scholarly journals Urinary Measurement of Epigenetic DNA Modifications: A Non-Invasive Assessment of the Whole-Body Epigenetic Status in Healthy Subjects and Colorectal Cancer Patients

ChemistryOpen ◽  
2016 ◽  
Vol 5 (6) ◽  
pp. 550-553 ◽  
Author(s):  
Rafal Rozalski ◽  
Daniel Gackowski ◽  
Agnieszka Siomek-Gorecka ◽  
Zbigniew Banaszkiewicz ◽  
Ryszard Olinski
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Whole Body ◽  
Non Invasive ◽  
Dna Modifications ◽  
Colorectal Cancer Patients

Phase II comparative study of capecitabine combined with oxaliplatin (XELOX) and CPT-11 (XELIRI) for advanced colorectal cancer patients (p) previously treated with 5-FU-based chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14544-14544
Author(s):  
J. L. Manzano ◽  
N. Díaz ◽  
C. Rolfo ◽  
I. Juez ◽  
J. M. Gracía-Bueno ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Disease Control ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Advanced Colorectal Cancer ◽  
Survival Rates ◽  
Dose Intensity ◽  
Line Treatment ◽  
Previously Treated ◽  
Colorectal Cancer Patients

14544 Background: Based on the results obtained with Capecitabine (XEL), Oxaliplatin (OX), and CPT-11 (IRI), we proposed this exploratory study to asses the efficacy of XELIRI and XELOX, for advanced colorectal cancer, after a first line treatment with 5 FU plus OX (FOLFOX) or IRI (FOLFIRI). Methods: P aged = 18 with histological diagnosis of metastatic colorectal adenocarcinoma, were assigned to XELOX arm (XEL, 1000 mg/m2 BID during 14 d; OX, 130 mg/m2 d1; q3w) or XELIRI arm (XEL 1000 mg/m2 BID during 14 d; IRI 240 mg/m2 d1; q3w), depending on previous treatment (FOLFIRI or FOLFOX, respectively). Although sample size was calculated for 115 p, recruitment was premature closed due to the low inclusion rate related with cetuximab + IRI approval for second line treatment. Results: Forty three p (25 p, XELOX; 18 p, XELIRI) were enrolled: median age 63.2 years; M/F, 40.5%/59.5%; ECOG PS 0–1, 79.1%. All p have been previously treated for metastatic disease and 65.1% had stage IV. Main sites of metastatic disease were liver (71.8%), lymph nodes (7.7%), pelvis (7.7 %) and lung (5.1%). XELOX/XELIRI treatment data: total number of administered cycles was 94/85 and median relative dose intensity 100%(XEL)/99%(OX) and 96%(XEL)/94%(IRI); disease control rate (PR+SD) was 28%/33.3%, median TTP 3.4/4.1 months, median OS 10.3/11.2 months and 1-year survival, 39.1%/44.3%, respectively. Twenty p (46.5%) received further antitumoral treatment. Most frequent G3–4 toxicities per p are detailed in table 1 . Conclusions: Capecitabine based combinations show an excellent toxicity profile and good efficacy results, in terms of disease control and survival rates, for advanced colorectal cancer patients previously treated with 5-FU schedules. [Table: see text] No significant financial relationships to disclose.

Association of Sugar Intake with Inflammation- and Angiogenesis-Related Biomarkers in Newly Diagnosed Colorectal Cancer Patients

2021 ◽  
pp. 1-8
Author(s):  
Kelly L. Stewart ◽  
Biljana Gigic ◽  
Caroline Himbert ◽  
Christy A. Warby ◽  
Jennifer Ose ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Newly Diagnosed ◽  
Sugar Intake ◽  
Colorectal Cancer Patients

Lack of Concordance among Nutritional Diagnostic Methods in Newly Diagnosed Colorectal Cancer Patients

2021 ◽  
pp. 1-8
Author(s):  
Samara Bomfim Gomes Campos ◽  
Samara Cléssya Lucena de Azevedo ◽  
Thaynara Roberto da Silva Gomes ◽  
Nassib Bezerra Bueno ◽  
Marília Oliveira Fonseca Goulart ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Diagnostic Methods ◽  
Newly Diagnosed ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document